ADVANCED VASCULAR THERAPIES, INC.

ADVANCED VASCULAR THERAPIES, INC. specializes in vascular medical device development, clinical support services, and minimally invasive therapeutic technologies for cardiovascular and peripheral vascular applications. The company leverages expertise in endovascular systems, catheter-based delivery platforms, and biocompatible material engineering to advance patient-centric vascular interventions. Key differentiators include precision device design, regulatory strategy for FDA clearance pathways, and integration of imaging-guided procedural technologies. Their technical focus centers on optimizing device performance in complex vascular anatomy, with particular emphasis on safety, durability, and procedural efficiency in high-risk patient populations. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal contract performance can be inferred. Consequently, no agency-specific work scope or relationship dynamics can be described. The company operates within the medical device and biotechnology sector, with primary alignment to NAICS categories related to surgical and medical instrument manufacturing and clinical research support. In practice, this translates to the design, prototyping, and preclinical validation of vascular intervention tools used in hospital-based procedural suites. The firm positions itself as a niche innovator in next-generation endovascular therapies, serving clinical and regulatory stakeholders in the interventional radiology and cardiology markets. ADVANCED VASCULAR THERAPIES, INC. is structured as a Women-Owned Small Business and holds formal certification as a Woman-Owned Business under federal small business programs. Headquartered in Lafayette, Indiana, the company maintains a focused operational footprint with a lean, agile team structure optimized for R&D-driven product development. Its government market positioning is aligned with innovation-focused procurement channels supporting advanced medical technologies, though no federal contract history is currently documented.